Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kavya Ramkumar"'
Autor:
Igor V. Zavarzin, L. V. Kovalenko, Nouri Neamati, Adrian Esqueda, Alexandra S. Nikitina, Srinivas Odde, Mikhail M. Krayushkin, Kavya Ramkumar, Vladimir N. Yarovenko
Publikováno v:
Molecules; Volume 15; Issue 6; Pages: 3958-3992
Molecules
Molecules, Vol 15, Iss 6, Pp 3958-3992 (2010)
Molecules
Molecules, Vol 15, Iss 6, Pp 3958-3992 (2010)
Raltegravir was the first HIV-1 integrase inhibitor that gained FDA approval for use in the treatment of HIV-1 infection. Because of the emergence of IN inhibitor-resistant viral strains, there is a need to identify innovative second-generation IN in
Publikováno v:
Medicinal research reviews. 30(6)
In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the adv
Autor:
Kavya, Ramkumar, Konstantin V, Tambov, Rambabu, Gundla, Alexander V, Manaev, Alexandr V, Manaev, Vladimir, Yarovenko, Valery F, Traven, Nouri, Neamati
Publikováno v:
Bioorganicmedicinal chemistry. 16(19)
HIV-1 integrase (IN) has emerged as an important therapeutic target for anti-HIV drug development. Its uniqueness to the virus and its critical role in the viral life cycle makes IN suitable for selective inhibition. The recent approval of Raltegravi
Publikováno v:
Retrovirology, Vol 6, Iss 1, p 25 (2009)
Retrovirology, Vol 6, Iss 1, p 33 (2009)
Retrovirology
Retrovirology, Vol 6, Iss 1, p 33 (2009)
Retrovirology
Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but